Payment overview · 2025
General Payments
$279.73
14 reported records · 6 companies
Healthcare provider profile · identity verified
Jeffrey W. Pro, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STATE COLLEGE, PA · NPI 1114980208
Verified facts
What the public records show
CMS Open Payments records show Jeffrey W. Pro, M.D. received $279.73 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.92 | 35.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.39 | 23.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.66 | 16.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.16 | 13.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.70 | 6.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.90 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.73 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.72 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.72 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.28 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 242 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
121 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 780 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 671 | 183 |
| Lisinopril | Lisinopril | 478 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 111 |
| Losartan Potassium | Losartan Potassium | 356 | 95 |
| Omeprazole | Omeprazole | 330 | 86 |
| Simvastatin | Simvastatin | 329 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 76 |
| Metformin Hcl | Metformin Hcl | 287 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 80 |
| Eliquis | Apixaban | 242 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 45 |
| Gabapentin | Gabapentin | 166 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 39 |
| Furosemide | Furosemide | 152 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 45 |
| Sertraline Hcl | Sertraline Hcl | 150 | 45 |
| Lorazepam | Lorazepam | 149 | 36 |
| Potassium Chloride | Potassium Chloride | 147 | 38 |
| Famotidine | Famotidine | 144 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 35 |
| Synthroid | Levothyroxine Sodium | 121 | 33 |
| Allopurinol | Allopurinol | 110 | 31 |
| Tramadol Hcl | Tramadol Hcl | 102 | 28 |
| Montelukast Sodium | Montelukast Sodium | 99 | 24 |
| Metformin Hcl Er | Metformin Hcl | 98 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 26 |
| Alprazolam | Alprazolam | 85 | 13 |
| Glimepiride | Glimepiride | 83 | 16 |
| Atenolol | Atenolol | 81 | 21 |
| Meloxicam | Meloxicam | 81 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 33 |
| Trazodone Hcl | Trazodone Hcl | 78 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 16 |
| Telmisartan | Telmisartan | 76 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 16 |
| Celecoxib | Celecoxib | 65 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 22 |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | 13 |
| Buspirone Hcl | Buspirone Hcl | 58 | 19 |
| Ozempic | Semaglutide | 58 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 13 |
| Trulicity | Dulaglutide | 53 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Finasteride | Finasteride | 52 | 14 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 13 |
| Carvedilol | Carvedilol | 49 | 14 |
| Meclizine Hcl | Meclizine Hcl | 47 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Spironolactone | Spironolactone | 44 | 11 |
| Valsartan | Valsartan | 42 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 14 |
| Xarelto | Rivaroxaban | 40 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 24 |
| Baclofen | Baclofen | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Prednisone | Prednisone | 32 | 15 |
| Valacyclovir | Valacyclovir Hcl | 32 | 11 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Indapamide | Indapamide | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 19 |
| Trimethoprim | Trimethoprim | 24 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Silodosin | Silodosin | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.73 · 14 records | ABBVIE INC. | AREXVY, BEXSERO, ELIQUIS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error